Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.38 |
| ▸ | MMP3 | P08254 | 4/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | MMP9 | P14780 | 2/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6433986 | 0.89 | HDAC3 (0.36) | MMP2MMP3MMP1 | |
| SCHEMBL6843604 | 0.86 | MMP2 (0.40) | MMP2MMP3MMP1MMP9POLB | |
| SCHEMBL8197265 | 0.73 | MMP2 (0.45) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL8422729 | 0.72 | MMP2 (0.43) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL8196211 | 0.69 | ALOX5 (0.45) | ALOX5 | |
| SCHEMBL10940804 | 0.68 | TRPA1 (0.56) | ALOX5TRPA1 | |
| SCHEMBL10942505 | 0.68 | TRPA1 (0.56) | ALOX5TRPA1 | |
| SCHEMBL10942249 | 0.68 | TRPA1 (0.56) | ALOX5TRPA1 | |
| SCHEMBL8777260 | 0.67 | MMP2 (0.55) | MMP2MMP3MMP1MMP9MMP14 | |
| SCHEMBL3170929 | 0.67 | TRPA1 (0.57) | ALOX5TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0740653-B1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1999-08-04 | — | — | EP | claimed |
| EP-0740653-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | claimed |
| WO-1995019957-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | claimed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| US-6133304-A | TREATING FIBROSIS, VENTRICULAR DILATION, AND/OR HEART FAILURE IN A MAMMAL BY ADMINISTERING AN ANTIFIBROTIC AMOUNT OF A MIXTURE OF AN ANGIOTENSIN-CONVERTING ENZYME(ACE) INHIBITOR AND AT LEAST ONE MATRIX METALLOPROTEINASE(MMP) INHIBITOR | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0740653-B1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1999-08-04 | — | — | EP | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| EP-0740653-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995019957-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |
| WO-1995019957-A1 | HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP2 19/4885MMP3 3/4885MMP1 20/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | MMP2 19/4885MMP3 3/4885MMP1 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.